Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;69(4):521-528.
doi: 10.1007/s10384-025-01204-4. Epub 2025 May 10.

Two-year outcomes of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration

Junki Hoshino  1 , Hidetaka Matsumoto  2 , Saki Numaga  1 , Kosuke Nakamura  1 , Hideo Akiyama  1
Affiliations

Two-year outcomes of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration

Junki Hoshino et al. Jpn J Ophthalmol. 2025 Jul.

Abstract

Purpose: We previously reported 1-year outcomes of a treat-and-extend (TAE) regimen with intravitreal faricimab (IVF) for treatment-naïve neovascular age-related macular degeneration (nAMD). Herein, we evaluated the second-year results of this TAE regimen with IVF in eyes completing the first-year treatment.

Study design: Retrospective, interventional case series.

Methods: We retrospectively studied 30 eyes with treatment-naïve nAMD that had completed the initial year of treatment, assessing best-corrected visual acuity (BCVA), foveal thickness (FT), central choroidal thickness (CCT), total number of injections over 2 years, and intended injection interval at the last visit.

Results: Twenty-five eyes completed the 2-year IVF treatment. There was no significant difference between pre-treatment and 2 years post-treatment BCVA. FT and CCT both showed significant reductions, maintained during the 2-year study period. The total number of injections was 10.1 ± 1.2 over the 2 years. The intended injection interval at the last visit was 13.0 ± 3.4 weeks. Of 5 eyes not completing 2 years of IVF treatment, 4 were switched to other anti-vascular endothelial growth factor (VEGF) agents due to persistent fluids despite IVF at 8-week intervals. In the remaining eye, IVF treatment was discontinued due to suspected faricimab-related intraocular inflammation.

Conclusions: The TAE regimen with IVF for treatment-naïve nAMD was effective during a 2-year period for improving exudative changes and maintaining visual acuity. Although IVF was found to be a relatively safe treatment for nAMD, there were cases requiring a switch to other anti-VEGF agents due to inadequate fluid control effect.

Keywords: Age-related macular degeneration; Anti-vascular endothelial growth factor; Faricimab; Treat-and-extend.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: J. Hoshino, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju); H. Matsumoto, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju), Participation on a Data Safety Monitoring Board or Advisory Board (Novartis, Chugai); S. Numaga, None; K. Nakamura, None; H. Akiyama, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju, Bayer, Santen, Otsuka, AMO, Pfizer, Wakamoto, Kowa, Eisai, HOYA).

Similar articles

See all similar articles

References

    1. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26. - PubMed
    1. Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol. 2021;65:741–60. - PubMed
    1. Regula JT, von Leithner PL, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88. - PubMed - PMC
    1. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40. - PubMed
    1. Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914–26. - PubMed

MeSH terms

LinkOut - more resources